肿瘤预防与治疗2024，Vol.37Issue(6)：519-524,6.DOI:10.3969/j.issn.1674-0904.2024.06.010
CDK4/6抑制剂在乳腺癌免疫微环境中的研究进展
Research Progress of CDK4/6 Inhibitors in the Immune Microenviron-ment of Breast Cancer
摘要
Abstract
Cyclin-dependent kinase 4 and 6(CDK4/6)is a class of serine/threonine kinases that normally bind to cyclin D and regulate cells transferring from the G1 phase to the S phase.In recent years,CDK4/6 inhibitors have improved surviv-al outcomes of patients with hormone receptor-positive breast cancer.And CDK4/6 inhibitors alone as well as CDK4/6 inhibi-tors combined with endocrine therapy have been used in patients with advanced breast cancer.However,drug resistance re-mains a key factor limiting the use of CDK4/6 inhibitors.In addition,CDK4/6 inhibitors combined with other immune-relat-ed targeted drugs has transformed the resistance of CDK4/6 inhibitors to some extent.This article focuses on the mechanism of and treatment with CDK4/6 inhibitors in the immune microenvironment of breast cancer,which provides evidence for sub-sequent research on CDK4/6 inhibitor combined with immune-related therapy.关键词
CDK4/6/CDK4/6抑制剂/免疫/免疫治疗Key words
CDK4/6/CDK4/6 inhibitor/Immunity/Immunotherapy分类
医药卫生引用本文复制引用
高雅楠,南璐,贾红燕..CDK4/6抑制剂在乳腺癌免疫微环境中的研究进展[J].肿瘤预防与治疗,2024,37(6):519-524,6.基金项目
This study was supported by Natural Science Foundation of Shanxi Province(No.201901D111347),and by grants from Department of Human Resources and Social Security of Shanxi Province(No.2020036). 山西省自然科学基金面上项目(编号:201901D111347) （No.201901D111347）
山西省留学人员科技活动择优资助项目(编号:2020036) （编号:2020036）
